DEA Extends Telehealth Prescribing Flexibilities for Controlled Substances

Complications: Health Policy Unraveled

The regulatory landscape for telehealth prescribing of controlled substances is evolving.

In episode 13 of Complications: Health Policy Unraveled, host Stephanie Kennan covers the DEA's recent extension of pandemic-era telehealth prescribing flexibilities for controlled substances through 2024, marking the second extension. Originally set to expire in May, these extensions followed extensive public input, including 38,000 comments and two telemedicine listening sessions. Advocates, including healthcare organizations and Congress members, stress the importance of telehealth for addressing issues like opioid use disorders. The DEA is currently reviewing feedback, leaving the final rules to be determined. Stay tuned for updates on this dynamic policy landscape.

Meet Your Host

Name: Stephanie Kennan

Title: Senior Vice President, Federal Public Affairs at McGuireWoods Consulting

Specialty: Stephanie Kennan helps clients navigate the legislative and executive branches of the federal government to solve problems involving a variety of healthcare policy issues. Her work focuses on providers, medical device manufacturers, drug manufacturers and associations concerned about Medicare and Medicaid reimbursement.

Connect: LinkedIn

Episode Highlights

[00:39] DEA and HHS announced they would extend the pandemic-era telehealth prescribing flexibilities for controlled substances through 2024

[01:46] Overview of what lead to the first temporary rule extension

[02:47] Overview of what lead to the second temporary rule extension

Contact

Connect with us on Facebook, Twitter, LinkedIn, YouTube.

Subscribe to Complications: Health Policy Unraveled in your preferred podcast app and never miss a healthcare update by subscribing to host and JD Supra’s #1 healthcare author Stephanie Kennan’s Washington Healthcare Update at www.mwcllc.com